Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell therapies into the clinic. Umoja’s only clinical-stage candidate is UB-TT170, a ...
- First landmark, peer-reviewed publication of successful in vivo CAR T-cell data in an immune competent NHP model -- Data validate the VivoVec™ platform in a translationally relevant model and ...
Chronicling the Seattle and Pacific Northwest startup scene. SEE MORE by Taylor Soper on Jan 14, 2025 at 8:55 am January 14, 2025 at 10:56 am Another Seattle-area health startup is raising a big new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results